Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

The Effect of 'Mindfulness of Breathing' on Chronic Migraine

13. November 2026 aktualisiert von: Dr Ashish Kumar Duggal, Dr. Ram Manohar Lohia Hospital

Migraine is a common disabling primary headache disorder ranked as the third most prevalent disorder in the world. Chronic migraine (CM) is described as a headache occurring on 15 or more days/month for more than 3 months, which, on at least 8 days/month, has the features of a migraine headache. Chronic migraine typically evolves from episodic migraine with an annual progression rate of ~3%. CM is an important treatable cause of neurological disability . It impacts, on an average, 1.4-2.2% of the global population and imposes a significant individual and socioeconomic burden with disability scores reported to be nearly twice as high.

It is vital to make a diagnosis and ensure that any concomitant medical or psychological conditions are treated in parallel with interventions aimed at reducing the biological tendency to headaches. The conventional treatment for migraine therapy is medical therapy. However only half of the patients respond to medications and preventive drug treatments; and about 10% discontinue medications due to adverse events. Moreover almost half of the patients are not satisfied with the present treatment. There is a clear need for additional preventive strategies in the current treatment regimens for migraines due to existing shortcomings of medical management of CM. In addition, there are other tactics that can be used, such as practicing alternative medicine through Yoga and Meditation.

Meditation has been found to help in reducing stress and changing the psychological state of a person. Mindfulness meditation has been derived from Vipassana, an age old meditation technique and has been practiced since long. Buddhist literature has detailed description about the techniques of Vipassana. Mindfulness of Breathing called as 'Anapanasati Meditation', in Buddhist scriptures is the first step in the practice of Vipassana meditation. It is a technique that involves observing natural and normal breathing. As it enters and exits the body our breath acts as a connection between our conscious and unconscious minds and the voluntary and involuntary processes of our body. By observing our breath, we can gain insight into the nature of our mind and its tendency to be inconsistent and fleeting.Slowly, this technique helps develop concentration of the mind and become calm. . It is a simple and scientific method that can be easily learned. Using Mindfulness of Breathing (Anapanasati) as a tool to reduce stress can be helpful in reducing the disability associated with migraines, as stress is a common trigger for migraines.

In the present study we aim to evaluate the beneficial effects of this simple meditation technique in management of CM.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

80

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 60 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:-1. All patients between 18-60 years of age fulfilling the criteria for chronic migraine as defined by ICHD -3.3 2. Patients willing to carry out meditation as prescribed. 3. Patients on a maximum of one concomitant preventive medication for not less than 3 months duration and a stable dose for at least 1 month prior to randomization.

Exclusion Criteria:-1. 1.Patients < 18 years and > 60 years of age. 2. Prior Neurologic diseases like brain tumors, dementia, seizures, encephalitis, meningitis, and stroke. 3. Patients overusing barbiturate-containing analgesics, opioids, or subjects with medical conditions attributable to medication overuse (e.g. peptic ulcer disease from overuse of nonsteroidal anti-inflammatory drugs [NSAIDS]).

4. Patients who did not complete the headache diary for more than 6 non-consecutive days during the baseline period.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Versorgungsforschung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Supervised Meditation Group

The 'Meditation' group will take part in structured 'Mindfulness of Breathing' meditation sessions. A total of five sessions will be conducted on days 0, 7, 14, 28 and week 8th at the Yoga Department of ABVIMS and Dr RML Hospital. These sessions will be supervised by a yoga instructor who will explain the procedure and answer any queries. The patients will then practice the meditation alongside the instructor, as described in the subsequent sections. They will also be encouraged to continue this practice daily at home, using a 20-minute audio guide featuring the voice of the 'Late Shri S.N. Goenka Ji'. Additionally, the 'Meditation group' will join a WhatsApp group for enhanced supervision by the Yoga instructor, in which members will be required to provide daily updates after their meditation sessions. If they fail to report their daily meditation, the admin would remind them to ensure that they complete it, and their queries and issues will also addressed.

The technique taught by the late Shri S.N. Goenka Ji involved sitting with closed eyes in a quiet room with minimal distractions, maintaining a comfortable posture with the spine straight and hands resting on the thighs, without requiring any specific mudra for 20 minutes daily.The practitioner will have to observe the breath as instructed, without judging its length or type. The nature of the breath will have to be accepted as it is and should not be altered. Any thoughts that arise are to be acknowledged without judgment. If the mind wanders, one has to notice this and gently shift awareness back to the breath without clinging to it or wishing it to be different. If any pain, discomfort, or other sensations are felt, these are to be acknowledged with awareness before returning attention to the breath. The subject simply follows the instructions of a pre-recorded 'Mindfulness of Breathing Meditation (Anapana)' audio provided by the yoga instructor throughout the sessions.

Schein-Komparator: Unsupervised Meditation Group

The Unsupervised meditation/Sham group will practice meditation on their visits-on days 0, 7, 14, 28, and week 8-without any supervision. The Yoga instructor will merely guide them once to independently concentrate on their breathing. They will not be provided any audio. This will serve as a sham group for more effective comparison and ensured blinding.

Patients were told to meditate on their own .They were not provided with any structured meditation technique. They were told to meditate in a quiet room with minimal distractions, maintaining a comfortable posture with the spine straight and hands resting on the thighs, without requiring any specific mudra for 20 minutes daily on their own without any specific instructions.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
To assess the change in headache days at 12 weeks from baseline.
Zeitfenster: From enrollment to 12 Weeks.

Change in frequency of moderate-severe headache days per month from baseline (Headache-day is defined as a calendar day [00:00 to 23:59] when the patient reported > 4 continuous hours of headache in the diary) during the month 2-3.

From enrollment to 12 Weeks.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Change in migraine days (week 8 - 12 vs baseline)
Zeitfenster: 12 weeks
12 weeks
50% responder rate
Zeitfenster: 12 weeks
12 weeks

Andere Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
Change in headache severity (week 8 - 12 vs baseline)
Zeitfenster: 12 weeks
12 weeks
Change in number of days with acute medication use (week 8 - 12 vs baseline)
Zeitfenster: 12 weeks
12 weeks
Change in PHQ-9 scores (week 8 - 12 vs baseline)
Zeitfenster: 12 weeks
12 weeks
Change in MIDAS score ( week 8-12 vs baseline)
Zeitfenster: 12 weeks
12 weeks
Change in HIT (week 8-12 vs baseline)
Zeitfenster: 12 weeks
12 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. November 2026

Primärer Abschluss (Geschätzt)

15. August 2027

Studienabschluss (Geschätzt)

15. August 2027

Studienanmeldedaten

Zuerst eingereicht

13. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2026

Zuerst gepostet (Tatsächlich)

19. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • IEC/ABVIMS/RMLH/1410

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

IPD related to the study will be shared by the principal investigator on request.

Art der unterstützenden IPD-Freigabeinformationen

  • STUDIENPROTOKOLL
  • SAFT
  • ICF

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .